HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus.

Abstract
X-linked nephrogenic diabetes insipidus (XNDI) is a severe kidney disease caused by inactivating mutations in the V2 vasopressin receptor (V2R) gene that result in the loss of renal urine-concentrating ability. At present,no specific pharmacological therapy has been developed for XNDI, primarily due to the lack of suitable animal models. To develop what we believe to be the first viable animal model of XNDI, we generated mice in which the V2R gene could be conditionally deleted during adulthood by administration of 4-OH-tamoxifen.Radioligand-binding studies confirmed the lack of V2R-binding sites in kidneys following 4-OH-tamoxifen treatment, and further analysis indicated that upon V2R deletion, adult mice displayed all characteristic symptoms of XNDI, including polyuria, polydipsia, and resistance to the antidiuretic actions of vasopressin. Gene expression analysis suggested that activation of renal EP4 PGE2 receptors might compensate for the lack of renal V2R activity in XNDI mice. Strikingly, both acute and chronic treatment of the mutant mice with a selective EP4 receptor agonist greatly reduced all major manifestations of XNDI, including changes in renal morphology.These physiological improvements were most likely due to a direct action on EP4 receptors expressed on collecting duct cells. These findings illustrate the usefulness of the newly generated V2R mutant mice for elucidating and testing new strategies for the potential treatment of humans with XNDI.
AuthorsJian Hua Li, Chung-Lin Chou, Bo Li, Oksana Gavrilova, Christoph Eisner, Jürgen Schnermann, Stasia A Anderson, Chu-Xia Deng, Mark A Knepper, Jürgen Wess
JournalThe Journal of clinical investigation (J Clin Invest) Vol. 119 Issue 10 Pg. 3115-26 (Oct 2009) ISSN: 1558-8238 [Electronic] United States
PMID19729836 (Publication Type: Journal Article)
Chemical References
  • Aqp2 protein, mouse
  • Aqp3 protein, mouse
  • Aquaporin 2
  • Methyl Ethers
  • ONO-AE1-329
  • PTGER4 protein, human
  • Ptger4 protein, mouse
  • Receptors, Prostaglandin E
  • Receptors, Prostaglandin E, EP4 Subtype
  • Receptors, Vasopressin
  • Aquaporin 3
Topics
  • Animals
  • Aquaporin 2 (metabolism)
  • Aquaporin 3 (metabolism)
  • Diabetes Insipidus, Nephrogenic (drug therapy, metabolism, pathology, physiopathology)
  • Disease Models, Animal
  • Gene Deletion
  • Genetic Diseases, X-Linked (drug therapy, metabolism, pathology, physiopathology)
  • Kidney (metabolism, pathology)
  • Kidney Concentrating Ability
  • Kidney Tubules, Collecting (cytology, metabolism)
  • Male
  • Methyl Ethers (therapeutic use)
  • Mice
  • Mice, Knockout
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Prostaglandin E (agonists, metabolism)
  • Receptors, Prostaglandin E, EP4 Subtype
  • Receptors, Vasopressin (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: